Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies
Survival Benefit in Children with Progeria Published in JAMA 2018
NDA Filing Planned in 2019
PALO ALTO, Calif., Dec. 19, 2018 -- (Healthcare Sales & Marketing Network) -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and ... Biopharmaceuticals, FDA Eiger BioPharmaceuticals, Lonafarnib, Progeria Syndrome, Progeroid Laminopathies
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news